CD163 and head and neck squamous cell carcinoma: To validate and further characterize the CD68/CD163 subsets as MΦ, we first examined single-cell mRNA datasets of two previously published studies in HNSCC patients for co-expression of CD68 and CD163 and other MΦ-specific markers.